Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 783

Similar articles for PubMed (Select 19429976)

1.

Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.

Dickinson PJ, Surace EI, Cambell M, Higgins RJ, Leutenegger CM, Bollen AW, LeCouteur RA, Gutmann DH.

Vet Pathol. 2009 Sep;46(5):884-92. doi: 10.1354/vp.08-VP-0251-D-FL. Epub 2009 May 9.

2.

Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival.

Surace EI, Lusis E, Murakami Y, Scheithauer BW, Perry A, Gutmann DH.

J Neuropathol Exp Neurol. 2004 Oct;63(10):1015-27.

PMID:
15535129
3.

Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas.

Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF.

Hum Mol Genet. 2000 Jun 12;9(10):1495-500.

4.

Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.

Ng HK, Lau KM, Tse JY, Lo KW, Wong JH, Poon WS, Huang DP.

Neurosurgery. 1995 Oct;37(4):764-73.

PMID:
8559307
5.

Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma.

Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, Gusella J, MacCollin M.

Cancer Genet Cytogenet. 2005 Oct 15;162(2):135-9.

PMID:
16213361
6.

The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts.

Pykett MJ, Murphy M, Harnish PR, George DL.

Hum Mol Genet. 1994 Apr;3(4):559-64.

PMID:
8069298
7.

Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.

Maxwell M, Shih SD, Galanopoulos T, Hedley-Whyte ET, Cosgrove GR.

J Neurosurg. 1998 Mar;88(3):562-9.

PMID:
9488313
8.

The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A.

Neoplasia. 2008 Nov;10(11):1204-12.

9.

Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.

Evans JJ, Jeun SS, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, Golubic M.

J Neurosurg. 2001 Jan;94(1):111-7.

PMID:
11147878
10.

Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.

Wellenreuther R, Waha A, Vogel Y, Lenartz D, Schramm J, Wiestler OD, von Deimling A.

Lab Invest. 1997 Dec;77(6):601-6.

PMID:
9426397
11.

Evaluation of NF2 gene deletion in pediatric meningiomas using chromogenic in situ hybridization.

Begnami MD, Rushing EJ, Santi M, Quezado M.

Int J Surg Pathol. 2007 Apr;15(2):110-5.

PMID:
17478763
12.

Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

Lekanne Deprez RH, Bianchi AB, Groen NA, Seizinger BR, Hagemeijer A, van Drunen E, Bootsma D, Koper JW, Avezaat CJ, Kley N, et al.

Am J Hum Genet. 1994 Jun;54(6):1022-9.

13.

Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.

Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF.

Vet Pathol. 2002 Jul;39(4):458-72.

14.

Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.

Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M.

Brain Pathol. 2008 Jan;18(1):62-70. Epub 2007 Oct 9.

15.

Altered expression of beta-catenin/E-cadherin in meningiomas.

Brunner EC, Romeike BF, Jung M, Comtesse N, Meese E.

Histopathology. 2006 Aug;49(2):178-87.

PMID:
16879395
16.

Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.

Kimura Y, Saya H, Nakao M.

Neuropathology. 2000 Sep;20(3):153-60. Review.

PMID:
11132929
17.

NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study.

Buccoliero AM, Castiglione F, R Degl'Innocenti D, Gheri CF, Garbini F, Taddei A, Ammannati F, Mennonna P, Taddei GL.

Neuropathology. 2007 Feb;27(1):36-42.

PMID:
17319281
18.

Reduced expression of schwannomin/merlin in human sporadic meningiomas.

Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubić M.

Neurosurgery. 1997 Mar;40(3):578-87.

PMID:
9055299
19.

Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.

Pykett MJ, Landers J, George DL.

J Neurooncol. 1997 Mar;32(1):39-44.

PMID:
9049861
20.

Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.

Buccoliero AM, Gheri CF, Castiglione F, Ammannati F, Gallina P, Taddei A, Garbini F, Rossi Degl'Innocenti D, Arganini L, Di Lorenzo N, Mennonna P, Taddei GL.

Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):353-7. Review.

PMID:
17721284
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk